(0.34%) 5 117.21 points
(0.34%) 38 369 points
(0.39%) 15 989 points
(-0.94%) $83.06
(5.25%) $2.02
(0.34%) $2 355.20
(0.54%) $27.68
(4.12%) $960.05
(-0.29%) $0.932
(-0.46%) $10.97
(-0.58%) $0.796
(1.66%) $93.40
Live Chart Being Loaded With Signals
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States...
Stats | |
---|---|
本日の出来高 | 106 032 |
平均出来高 | 228 838 |
時価総額 | 82.44M |
EPS | €0 ( 2024-03-27 ) |
次の収益日 | ( €-0.240 ) 2024-05-09 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -1.690 |
ATR14 | €0.0130 (0.92%) |
ボリューム 相関
Inflarx NV 相関
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Inflarx NV 相関 - 通貨/商品
Inflarx NV 財務諸表
Annual | 2023 |
収益: | €61 795.00 |
総利益: | €-957 050 (-1 548.75 %) |
EPS: | €-0.760 |
FY | 2023 |
収益: | €61 795.00 |
総利益: | €-957 050 (-1 548.75 %) |
EPS: | €-0.760 |
FY | 2022 |
収益: | €0 |
総利益: | €-585 852 (0.00 %) |
EPS: | €-0.610 |
FY | 2021 |
収益: | €0.00 |
総利益: | €0.00 (0.00 %) |
EPS: | €-1.100 |
Financial Reports:
No articles found.
Inflarx NV
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。